{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:23:56Z","timestamp":1791559436381,"version":"4.3.4"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,2]]},"DOI":"10.7759\/cureus.111955","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T16:35:15Z","timestamp":1783010115000},"source":"Crossref","is-referenced-by-count":1,"title":["Severe Pulmonary-Renal Syndrome Due to Hydralazine-Induced ANCA-Associated Vasculitis"],"prefix":"10.7759","author":[{"given":"Ayomide O","family":"Gbenle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puneet","family":"Bedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Spitalewitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bakhtyar","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.03.029","article-title":"Anti-neutrophil cytoplasmic antibody associated glomerulonephritis complicating treatment with hydralazine","volume":"100","author":"Santoriello D","year":"2021","unstructured":"Santoriello D, Bomback AS, Kudose S, et al.. Anti-neutrophil cytoplasmic antibody associated glomerulonephritis complicating treatment with hydralazine. Kidney Int. 2021, 100:440-6. 10.1016\/j.kint.2021.03.029","journal-title":"Kidney Int"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2018.01.005","article-title":"Hydralazine-associated vasculitis: overlapping features of drug-induced lupus and vasculitis","volume":"48","author":"Kumar B","year":"2018","unstructured":"Kumar B, Strouse J, Swee M, Lenert P, Suneja M. Hydralazine-associated vasculitis: overlapping features of drug-induced lupus and vasculitis. Semin Arthritis Rheum. 2018, 48:283-7. 10.1016\/j.semarthrit.2018.01.005","journal-title":"Semin Arthritis Rheum"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1172\/JCI178813","article-title":"Sequential carbonyl derivatives and hydrazone adduct formation on myeloperoxidase contribute to development of ANCA vasculitis","volume":"135","author":"Xi G","year":"2025","unstructured":"Xi G, Mclnnis EA, Lardinois O, et al.. Sequential carbonyl derivatives and hydrazone adduct formation on myeloperoxidase contribute to development of ANCA vasculitis. J Clin Invest. 2025, 135:10.1172\/JCI178813","journal-title":"J Clin Invest"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2023.10.008","article-title":"KDIGO 2024 clinical practice guideline for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis","volume":"105","year":"2024","unstructured":"KDIGO 2024 clinical practice guideline for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Kidney Int. 2024, 105.S71-S116. 10.1016\/j.kint.2023.10.008","journal-title":"Kidney Int"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2025.103924","article-title":"Drug- and vaccine induced ANCA-associated vasculitis: an overview","volume":"25","author":"Cohen Tervaert JW","year":"2026","unstructured":"Cohen Tervaert JW. Drug- and vaccine induced ANCA-associated vasculitis: an overview. Autoimmun Rev. 2026, 25:103924. 10.1016\/j.autrev.2025.103924","journal-title":"Autoimmun Rev"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(19)30077-3","article-title":"Disease heterogeneity in antineutrophil cytoplasmic antibody-associated vasculitis: implications for therapeutic approaches","volume":"1","author":"Ford JA","year":"2019","unstructured":"Ford JA, Monach PA. Disease heterogeneity in antineutrophil cytoplasmic antibody-associated vasculitis: implications for therapeutic approaches. Lancet Rheumatol. 2019, 1:247-56. 10.1016\/S2665-9913(19)30077-3","journal-title":"Lancet Rheumatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/art.41773","article-title":"2021 American College of Rheumatology\/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis","volume":"73","author":"Chung SA","year":"2021","unstructured":"Chung SA, Langford CA, Maz M, et al.. 2021 American College of Rheumatology\/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 2021, 73:1366-83. 10.1002\/art.41773","journal-title":"Arthritis Rheumatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone JH","year":"2010","unstructured":"Stone JH, Merkel PA, Spiera R, et al.. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010, 363:221-32. 10.1056\/NEJMoa0909905","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1803537","article-title":"Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis","volume":"382","author":"Walsh M","year":"2020","unstructured":"Walsh M, Merkel PA, Peh CA, et al.. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N Engl J Med. 2020, 382:622-31. 10.1056\/NEJMoa1803537","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.2025-0796","article-title":"Management of antineutrophil cytoplasmic antibody-associated alveolar hemorrhage: a Bayesian reanalysis of the PEXIVAS trial","author":"Arbiv OA","year":"2026","unstructured":"Arbiv OA, Fidler L, Johnson SR, Gershon AS, Liu K. Management of antineutrophil cytoplasmic antibody-associated alveolar hemorrhage: a Bayesian reanalysis of the PEXIVAS trial. J Rheumatol. 2026, 10.3899\/jrheum.2025-0796","journal-title":"J Rheumatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/503297-severe-pulmonary-renal-syndrome-due-to-hydralazine-induced-anca-associated-vasculitis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T16:35:16Z","timestamp":1783010116000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/503297-severe-pulmonary-renal-syndrome-due-to-hydralazine-induced-anca-associated-vasculitis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.111955","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,2]]}}}